Antacid Medicines Improve Overall Survival in Head and Neck Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Cancer Prevention Research, researchers from the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, have found that patients with head and neck cancer who used antacids, like proton pump inhibitors and histamine 2 receptor antagonists, to treat heart burn and indigestion had better overall survival rates compared with those who did not use them.
For the study, researchers analyzed data of 596 patients treated for head and neck cancer. Of those, more than two-thirds took histamine 2 receptor antagonists, proton pump inhibitors, or both.
Results showed that among those that took proton pump inhibitors, such as omeprazole, esomeprazole, and pantoprazole, had a 45% decreased mortality risk compared with those who did not take the medications.
Patients who took histamine 2 receptor antagonists, which include cimetidine, ranitidine, and famotidine, had a 33% decreased mortality risk compared with those did not take the antacids.
Patients with head and neck cancer who are treated with chemotherapy and radiation often experience reflux, leading to wide use of antacids as a treatment for the adverse effect; however, the findings suggest that antacids like proton pump inhibitors and histamine 2 blockers also have a positive impact on overall survival.
Antacids had better overall survival rates compared with those who did not use them.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML